Back

Improving risk stratification in TAVI: the role of epicardial fat, visceral fat and adiponectin

29 August 2025 (10:45 - 10:55)
Organised by: Logo
Congress Presentation Part of: Predictors of TAVI outcomes Epidemiology, Prognosis, Outcome ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Tatyana Storozhenko

Cardiovascular Research Center Aalst, Aalst (Belgium)

5 More presentations in this session

Presentation thumbnail
Clinical outcomes and predictors of mortality in TAVI patients with high, low and very low baseline gradient. Analysis of the Spanish TAVI registry
Doctor J. De La Torre Hernandez (Santander, ES)
Abstract Slides Video
Presentation thumbnail
Periprocedural, early, and late outcomes following transcatheter aortic valve replacement in patients with severe aortic atheroma
Doctor S. Kikuchi (Strasbourg, FR)
Abstract Slides Video
Presentation thumbnail
A geriatric assessment score for predicting one-year survival after transcatheter aortic valve implantation: the multicenter GASS-TAVI study
Doctor C. Fumagalli (Naples, IT)
Abstract Slides Video
Presentation thumbnail
Impact of conduction disturbances persistency on 2-year outcomes after transcatheter aortic valve implantation
Doctor S. Okita (Chiba, JP)
Abstract Slides Video
Presentation thumbnail
Skirted prosthetic valves are associated with increased risk of subclinical leaflet thrombosis following transcatheter aortic valve replacement: a multicenter study
Doctor Y. Yang (Beijing, CN)
Abstract Slides Video

Access the full session

Session thumbnail
Predictors of TAVI outcomes
Video

The Event

Event poster

ESC Congress 2025

29 August 2025 10:45 CET
You may be interested in
thumbnail
Congress Session
The intricate interplay between fat and the heart
thumbnail
Congress Presentation
Automated radiomic profiling of epicardial adiposity for heart failure risk stratification: a multi-center study
thumbnail
Congress Presentation
Epicardial adipose tissue volume is related to subclinical atherosclerosis and major adverse cardiac events in asymptomatic subjects

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources